DoW Traumatic Brain Injury and Psychological Health, Clinical Trial Award

Key Facts

Status: Open

Posted date: May 6, 2026

Opportunity ID: 362187

Opportunity number: HT942526TBIPHRPCTA

Opportunity category: Discretionary

Agency name: Dept. of the Army -- USAMRAA

Agency code: DOD-AMRAA

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Grant
Category of Funding Activity
  • Science and Technology and other Research and Development
Eligible Applicants
  • Unrestricted
Tools
Categories (use these for quoted searches)
  • agency_code:dod_amraa
  • category_of_funding_activity:science_and_technology_and_other_research_and_development
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:unrestricted
  • funding_instrument_type:grant
  • opportunity_category:discretionary
  • status:open
Description

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines. Distinctive Features: Funding from this award mechanism must support a clinical trial. · Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies. · Preliminary data are required. · The inclusion of community-based participatory research (CBPR) approaches is required. · The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research. ○ Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials. ○ Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations. · Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award. https://cdmrp.health.mil/pubs/press/2026/tbiphrppreann

DoW Traumatic Brain Injury and Psychological Health, Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines. Distinctive Features: Funding from this award mechanism must support a clinical trial. · Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies. · Preliminary data are required. · The inclusion of community-based participatory research (CBPR) approaches is required. · The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research. ○ Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials. ○ Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations. · Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award. https://cdmrp.health.mil/pubs/press/2026/tbiphrppreann
DoW Traumatic Brain Injury and Psychological Health, Clinical Trial Award
Open
Dept. of the Army -- USAMRAA
Science and Technology and other Research and Development
Grant
Unrestricted
2026-05-06